Eli Lilly's EloraTZP Shows Greater Weight and A1C Reduction in Phase 2b Trial
Eli Lilly's experimental drug EloraTZP, a combination of eloralintide and tirzepatide, demonstrated superior weight loss and A1C reduction compared to tirzepatide 15 mg in a 48-week Phase 2b study. Participants taking EloraTZP lost significantly more weight and saw greater improvements in their blood sugar levels.
